Navigation Links
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
Date:10/8/2007

SAN DIEGO, Oct. 8 /PRNewswire/ -- Ocera Therapeutics, Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat gastrointestinal and liver diseases announced today that it has completed the patient enrollment of its Phase 3 study in fistulizing Crohn's disease. This pivotal, double-blind, placebo controlled study, FHAST1 (Fistula Healing with AST-120), has been designed to determine the efficacy and safety of oral AST-120 in 240 patients with Crohn's disease suffering from perianal fistulas. Initial data from the trial will be available in the first quarter of 2008.

"We are very pleased to have completed the enrollment in our FHAST1 pivotal trial evaluating AST-120 in a timely manner," stated Laurent Fischer, M.D., President and CEO of Ocera Therapeutics. "We would like to thank our investigators and patients in North America, Europe and Israel for their participation in the study."

Data from a double blind, placebo controlled Japanese study of AST-120 in fistulizing Crohn's disease sponsored by Kureha and presented at the Digestive Disease Week in May 2006 demonstrated that AST-120 significantly reduces draining fistulas compared to placebo.

"Up to one third of patients with Crohn's disease suffer from draining perianal fistulas, a chronic and debilitating condition that significantly affects their quality of life," said Professor Stephen Hanauer, M.D., Director of the Section of Gastroenterology and Nutrition at the University of Chicago and the Principal Investigator in the study. "Despite effective treatments, there is an unmet need for new and well-tolerated oral agents for patients with mild to moderate Crohn's disease who suffer from fistulas."

"We were pleased to participate in this Phase 3 trial evaluating the efficacy and safety of AST-120, a new oral treatment option, in fistulizing Crohn's disease," added Professor Simon Travis, M.D., Clinical Directo
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
5. Celsion Completes Enrollment in Phase I Liver Cancer Study
6. LANI completes Phase I in Japan and to commence Phase I in UK
7. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
11. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014  Amgen (NASDAQ: AMGN ) today ... M.D., president of Gladstone Institutes and Gladstone,s Robert W. ... "We are pleased to welcome Dr. Sandy Williams ... Bradway , chairman and chief executive officer of Amgen. ... and his direct experience in our industry will both ...
(Date:10/17/2014)... DALLAS , October 17, 2014 /PRNewswire/ ... research report "Optical Imaging Market by Technique (Optical ... System, Imaging software) & by Application (Ophthalmology, Neurology, Oncology, ... by MarketsandMarkets, this report studies the Optical Imaging ... The market was valued at $917.1 million ...
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
Breaking Medicine Technology:Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 2Amgen Announces Appointment Of R. Sanders Williams To Board Of Directors 3Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... A new study by researchers from Children,s Mercy ... that rapid electronic review of children,s heart images by ... and treatment of potentially serious pediatric heart problems. The ... National Conference and Exhibition in San Francisco. ...
... LAKES, N.J., Oct. 4 Medco Health Solutions, ... announce its third-quarter 2010 financial results in a ... November 2, 2010.   (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... release, management will hold a conference call at ...
Cached Medicine Technology:New Study Shows Telemedicine Works to Effectively Identify Heart Problems in Children Far from a Specialized Medical Center 2Medco Announces Date for Third-Quarter 2010 Financial Results 2
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... Principle Business Enterprises, a family owned company ... absorbent products. The company has recently made efforts ... Tranquility® Premium Protection absorbent products. The company has ... packaging a new look, and is currently working on ... public. , The new website, developed with Thread Marketing ...
(Date:10/20/2014)... October 20, 2014 Succeed is proud to ... companies who participated in the Every Body Walk! ... public awareness project that encourages workers to be more active ... 10,000 Program, which concluded at the end of September, was ... cities and metro areas. Participating companies gave their staff ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center for ... ROI on membership dues at 12.5. In other words, for ... value to member hospitals. The calculation used to determine member ... , “This is the first time we’ve actually been able ... is really sound,” said Bill Ryan , president and ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... , ... products and services provider DHS Technologies LLC recently revealed its newest shelter system – ... ... Technologies LLC recently revealed its newest shelter system – the Reeves Mobile Vaccination System., ...
... ... income in the current economy, and who are looking to better their health, too, can ... enlisting interested business leaders nationwide., , ... (PRWEB) March 16, 2010 -- Independent businessman Brad Aspin and leading health and wellness ...
... Large amounts of frozen plasma are being used inappropriately, ... Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj081933.pdf ... the clinical use of red blood cells and platelets ... of frozen plasma. "Two recent studies in Canada ...
... ... ... SAN RAFAEL, Calif. , March 15 The following was released today by the Marin Institute: , ... , , ...
... March 15 Spotlighting the importance of oral health care for expectant mothers, the California Dental Association (CDA) Foundation has released new guidelines designed to emphasize the safety of ... ... ... ...
... , March 15 The Board of Directors of Healthcare Trust of America, Inc. ("HTA"), ... June 2010 .  These distributions will be calculated based on the stockholders of record each day ... $10.00 . , ... ...
Cached Medicine News:Health News:DHS Technologies Unveils New Mobile Vaccination System 2Health News:Brad Aspin and Health and Wellness Company GBG Now Looking for Leaders Nationwide 2Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 2Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 3Health News:Advocates Rally Southland Assembly Health Committee Members to Pass AB 1694 4Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 2Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 3Health News:California Dental Association Foundation Releases New Oral Health Guidelines for Pregnant Women 4Health News:Healthcare Trust of America Board of Directors Declares Distributions 2Health News:Healthcare Trust of America Board of Directors Declares Distributions 3
Marquette General Health System Reference Laboratory provides a full range of testing including, Chemistry, Hematology, Coagulation, Urinalysis, Microbiology, Cytology, Anatomic Pathology, Flow Cytom...
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... national reference laboratory and a laboratory ... an extensive test menu of highly ... clinical and anatomic pathology. Owned by ... clients include university teaching hospitals and ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Medicine Products: